Manidipine dihydrochloride NEW
| Price | $42 | $68 |
| Package | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-17 |
Product Details
| Product Name: Manidipine dihydrochloride | CAS No.: 89226-75-5 |
| Purity: 100% | Supply Ability: 10g |
| Release date: 2024/11/17 |
Product Introduction
Bioactivity
| 名稱 | Manidipine dihydrochloride |
| 描述 | Manidipine dihydrochloride (Manidipine 2HCl) is a potent calcium channel blocker for Ca2+ current(IC50=2.6 nM). |
| 細(xì)胞實驗 | The mitogenic effect is measured by the amout of [3H]thymidine incorporated into DNA of human MCs and by assessment of cell proliferation. In brief, 1 × 105 quiescent cells is seeded into a 25-mL cell culture bottle and kept in low serum medium (0.1% FCS). On the following day, the cells are preincubated for 3 hours with Manidipine (10 nM) followed by stimulation with PDGF-BB (10 ng/mL) or incubated with low serum medium abone. The medium is replaced each day, and the cells are counted at days 1, 3 and 5.(Only for Reference) |
| 體外活性 | At nanomolar concentrations, Manidipine effectively modulates gene transcription involved in the inflammatory transformation of mesangial cells. Manidipine inhibits the coronary artery (pIC50=9.3 nM) and renal artery (pIC50=9.1 nM). Additionally, Manidipine decreases Ca2+ flux at concentrations above 0.1 nM and blocks Ca2+ flux at 100 nM. |
| 體內(nèi)活性 | In hypertensive rats, oral administration of Manidipine (3 mg/kg and 10 mg/kg) reduced systolic blood pressure in a dose-dependent manner. When administered at a dose of 10 mg/kg, Manidipine was able to normalize blood pressure within 1 to 3 hours post-administration. |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 60 mg/mL (87.77 mM) |
| 關(guān)鍵字 | Ca channels | Ca2+ channels | Manidipine dihydrochloride | CV4093 | Inhibitor | CV 4093 | Manidipine Dihydrochloride | Manidipine | inhibit | Calcium Channel |
| 相關(guān)產(chǎn)品 | Nisoldipine | Nimodipine | 2,5-Di-tert-butylhydroquinone | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | Lanthanum(III) chloride heptahydrate | Ethyl cinnamate | 1-Octanol | Otilonium bromide |
| 相關(guān)庫 | 疼痛相關(guān)化合物庫 | 經(jīng)典已知活性庫 | 膜蛋白靶向化合物庫 | 抗癌臨床化合物庫 | 藥物功能重定位化合物庫 | 抑制劑庫 | 神經(jīng)保護(hù)化合物庫 | 抗癌上市藥物庫 | 已知活性化合物庫 | 離子通道庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $68.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-17 | |
| $0.00/20Kg |
VIP1Y
|
Xuchang Hengsheng Pharmaceutical Co., Ltd
|
2024-08-07 | |
| $450.00/1KG |
Weijer International Trade (Hebei) Co., Ltd
|
2023-03-17 | ||
| $1.00/1mg |
ANHUI SHENGZHIKAI BIOTECHNOLOGY CO.,LTD
|
2022-06-15 | ||
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
| $1.00/50g |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-06-10 | |
| $0.00/1KG |
VIP5Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-05-11 | |
| $1.00/1kg |
Hebei Jimi Trading Co., Ltd.
|
2019-04-11 | ||
| $100.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-07-26 | |
| $9.00/50G |
Hebei Jiangkai Trading Co., Ltd
|
2018-04-27 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY